Q-omics provides the consensus-scored OR10G2 profile across patient tissues and cancer cell-line models. OR10G2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, OR10G2 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, OR10G2 RNA expression shows 6,940 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, LUAD, and THYM as cancer lineages where OR10G2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR10G2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR10G2 survival associations across molecular data types. OR10G2 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR10G2 RNA expression–survival associations across cancer types. High OR10G2 expression shows unfavorable associations in MESO, KIRC, LGG and READ, but favorable associations in HNSC and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for OR10G2 RNA expression.
This table summarizes OR10G2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR10G2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR10G2 shows lower tumor expression in LUSC and THCA and higher tumor expression in LUAD, BRCA, KIRC and PRAD. The LUAD box plot shows higher OR10G2 RNA expression in tumor versus normal tissue (log2 FC = +0.101, t-test p < 0.001).
This table shows molecular features associated with OR10G2 in patient tissues and cancer cell lines. In patient samples, OR10G2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, OR10G2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
